Rising Regulatory Costs And Shifting Consumer Preferences Will Undermine Performance

Key Takeaways

• Rising regulatory costs and evolving health guidelines threaten margins, while core product reformulation may constrain long-term earnings and growth.
  
• Shifting consumer preferences and weak innovation expose Haleon to declining demand, competitive pressures, and limited ability to defend its leading brands.
  
• Innovation, emerging market expansion, strong brands, and operational discipline drive resilient growth and position Haleon to benefit from long-term trends in global health and wellness.

Catalysts

About Haleon

Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

What are the underlying business or industry changes driving this perspective?

• Increasing regulatory scrutiny and changing consumer health guidelines threaten to drive up ongoing compliance costs and may require the reformulation or withdrawal of certain products, compressing Haleon's margins and reducing its ability to grow net earnings over time.
  
• Shifting consumer preferences towards natural and holistic remedies are set to erode demand for traditional over-the-counter pharmaceuticals, weakening the core revenue streams that Haleon depends on and ultimately leading to lower long-term revenue growth.
  
• The ongoing exposure to macroeconomic challenges-such as elevated inflation, currency devaluation in key emerging markets, and weakening consumer spending-means Haleon faces continued headwinds to both revenue and bottom-line growth, with recent results already highlighting a negative impact from foreign exchange rates that weighs on both revenues and profits.
  
• Heavy reliance on a limited set of well-known OTC brands makes Haleon increasingly vulnerable to competitive pressures from generics and private-label products, which could lead to persistent share losses, gross margin erosion, and a diminished ability to protect long-term earnings power.
  
• A less robust innovation pipeline relative to larger pharmaceutical competitors may limit Haleon's capacity to offset category declines or launch transformative products, resulting in capped revenue potential and stagnant earnings as consumer preferences and regulatory expectations continue to evolve.

Haleon Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Haleon compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Haleon's revenue will grow by 4.0% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 15.1% today to 16.2% in 3 years time.
• The bearish analysts expect earnings to reach £2.0 billion (and earnings per share of £0.24) by about July 2029, up from £1.7 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as £2.3 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 16.7x on those 2029 earnings, down from 18.5x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 18.4x.
• The bearish analysts expect the number of shares outstanding to decline by 1.35% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.38%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• There is strong innovation across Haleon's categories, as evidenced by successful launches like Clinical White in Oral Health, expansion into new geographies, and robust pipelines in vitamins and pain relief, which support higher revenue growth and margin resilience over time.
  
• The company is aggressively expanding its presence in emerging markets such as India and China, investing in its own salesforce and integrating acquisitions, which positions Haleon to capture long-term secular growth in markets with increasing disposable income and healthcare awareness, ultimately driving higher top-line growth.
  
• Haleon maintains a unique global footprint with leading consumer health brands like Centrum, Caltrate, and Sensodyne, fostering brand loyalty and share gains even during volatile markets, which supports stable or increasing revenues and resilient gross margins.
  
• The company demonstrates strong operational discipline, delivering working capital improvements, continued investment in R&D and advertising, and effective capital allocation including share buybacks, which together promote earnings growth and support valuation multiples.
  
• The shift in industry preference from prescription to OTC products, alongside growing health and wellness awareness in aging and middle-class populations worldwide, sustains demand for Haleon's product portfolio, creating long-term tailwinds for revenue and earnings expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Haleon is £3.15, which represents up to two standard deviations below the consensus price target of £4.14. This valuation is based on what can be assumed as the expectations of Haleon's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £5.12, and the most bearish reporting a price target of just £3.15.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be £12.4 billion, earnings will come to £2.0 billion, and it would be trading on a PE ratio of 16.7x, assuming you use a discount rate of 7.4%.
• Given the current share price of £3.5, the analyst price target of £3.15 is 11.3% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.